<span style="margin-left: 0em;">chemotherapy</span> <span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">placebo plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">pembrolizumab plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (4) progression or deaths (PFS) (4) objective responses (ORR) (4) DOR (4) AE (any grade) (2) TRAE (any grade) (2) AE leading to treatment discontinuation (any grade) (2) AE (grade 3-4) (2) AE leading to death (grade 5) (2) Peripheral neuropathy TRAE (grade 3-4) (3) Rash TRAE (grade 3-4) (2) Diarrhoea TRAE (grade 3-4) (2) Hypothyroidism TRAE (grade 3-4) (2) Fatigue TRAE (grade 3-4) (2) Nausea TRAE (grade 3-4) (2) Anaemia TRAE (grade 3-4) (2) Decreased appetite TRAE (grade 3-4) (2) Asthenia TRAE (grade 3-4) (2) Dry skin TRAE (grade 3-4) (2) Thrombocytopenia TRAE (grade 3-4) (2) Neutropenia TRAE (grade 3-4) (2) Vomiting TRAE (grade 3-4) (2) Constipation TRAE (grade 3-4) (2) Leucopenia TRAE (grade 3-4) (2) Alopecia TRAE (grade 3-4) (2) Pruritus TRAE (grade 3-4) (2) Weight decreased TRAE (grade 3-4) (2) Mucosal inflammation TRAE (grade 3-4) (2) Dysgeusia TRAE (grade 3-4) (2) Stomatitis TRAE (grade 3-4) (2) Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) (2) Blood creatinine increased TRAE (grade 3-4) (2) Dizziness TRAE (grade 3-4) (2) Peripheral sensory neuropathy TRAE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
2 KEYNOTE-062 (P vs C ; CPS>10), 2020
KEYNOTE-062 (P vs C ; CPS>1), 2020 2 KEYNOTE-062 (PC vs C ; CPS>1), 2020
KEYNOTE-062 (PC vs C ; CPS>10), 2020 pembrolizumab alone vs. pembrolizumab plus SoC
1.00 [0.79; 1.27] 1.00 [0.79;1.27]pembrolizumab alone vs. pembrolizumab plus SoC
1.00 [0.79; 1.27] pembrolizumab alone vs. Standard of Care (SoC)
0.85 [0.71; 1.01] 0.85 [0.71;1.01]pembrolizumab alone vs. Standard of Care (SoC)
0.85 [0.71; 1.01] pembrolizumab plus SoC vs. pembrolizumab alone
1.00 [0.79; 1.27] 1.00 [0.79;1.27]pembrolizumab plus SoC vs. pembrolizumab alone
1.00 [0.79; 1.27] pembrolizumab plus SoC vs. Standard of Care (SoC)
0.85 [0.72; 1.00] 0.85 [0.72;1.00]pembrolizumab plus SoC vs. Standard of Care (SoC)
0.85 [0.72; 1.00] Standard of Care (SoC) vs. pembrolizumab alone
1.18 [0.99; 1.40] 1.18 [0.99;1.40]Standard of Care (SoC) vs. pembrolizumab alone
1.18 [0.99; 1.40] Standard of Care (SoC) vs. pembrolizumab plus SoC
1.18 [1.00; 1.39] 1.18 [1.00;1.39]Standard of Care (SoC) vs. pembrolizumab plus SoC
1.18 [1.00; 1.39] Standard of Care (SoC) placebo plus SoC pembrolizumab alone pembrolizumab plus SoC direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C Standard of Care (SoC) placebo plus SoC pembrolizumab alone pembrolizumab plus SoC Standard of Care (SoC) --- NA 1.18 0.99; 1.401.18 1.00; 1.39placebo plus SoC NA --- NA NA pembrolizumab alone 0.85 0.71; 1.01NA --- 1.00 0.79; 1.27pembrolizumab plus SoC 0.85 0.72; 1.00NA 1.00 0.79; 1.27---
pathologies: 184
- treatments: 873
result logic